Clinical stage I (CS I) seminoma has been the subject of various studies aimed at finding the ideal treatment. Due to its high radiosensitivity, radiotherapy has been the standard approach for decades. However, the fact that CS I seminoma has a recurrence rate of only 15–20% has prompted many suggestions for better treatment stratification offering surveillance therapy for a subgroup of patients. Moreover, carboplatinum-based monochemotherapy has been the topic of various retrospective studies demonstrating equal effectiveness for adjuvant chemotherapy with one cycle of carboplatin. Since seminoma affects men in their mid-30s, only few reports have been published on long-term survival with reference to radiotoxicity and secondary malignancies. Long-term side effects and secondary malignancies pose an increasing problem for long-term survivors of primary malignancies treated by chemo- or radiotherapy. This becomes evident after a follow-up of 15 years. Since recent studies have disclosed unexpectedly high long-term morbidity and mortality after irradiation, this article critically reviews the value of radiotherapy and carboplatinum-based chemotherapy as equally effective treatment options for CS I seminoma.

Keywords:
Chemotherapy, Clinical stage I, Radiotherapy, Seminoma, Surveillance
1.
Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1999. CA Cancer J Clin 1999;49:8–31.
2.
Classen J, Schmidberger H, Meisner C, Souchon R, Sautter-Bihl ML, Sauer R, Weinknecht S, Kohrmann KU, Bamberg M: Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 2003;21:1101–1106.
3.
Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, Fossa SD, Skakkebaek NE, de Wit R, Fizazi K, Droz JP, Pizzocaro G, Daugaard G, de Mulder PH, Horwich A, Oliver T, Huddart R, Rosti G, Paz Ares L, Pont O, Hartmann JT, Aass N, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Classen J, Clemm S, Culine S, de Wit M, Derigs HG, Dieckmann KP, Flasshove M, Garcia del Muro X, Gerl A, Germa-Lluch JR, Hartmann M, Heidenreich A, Hoeltl W, Joffe J, Jones W, Kaiser G, Klepp O, Kliesch S, Kisbenedek L, Koehrmann KU, Kuczyk M, Laguna MP, Leiva O, Loy V, Mason MD, Mead GM, Mueller RP, Nicolai N, Oosterhof GO, Pottek T, Rick O, Schmidberger H, Sedlmayer F, Siegert W, Studer U, Tjulandin S, von der Maase H, Walz P, Weinknecht S, Weissbach L, Winter E, Wittekind C: European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004;15:1377–1399.
4.
Patel MI, Motzer RJ, Sheinfeld J: Management of recurrence and follow-up strategies for patients with seminoma and selected high-risk groups. Urol Clin North Am 2003;30:803–817.
5.
Vuky J, Tickoo SK, Sheinfeld J, Bacik J, Amsterdam A, Mazumdar M, Reuter V, Bajorin DF, Bosl GJ, Motzer RJ: Salvage chemotherapy for patients with advanced pure seminoma. J Clin Oncol 2002;20:297–301.
6.
Fossa SD, Horwich A, Russell JM, Roberts JT, Cullen MH, Hodson NJ, Jones WG, Yosef H, Duchesne GM, Owen JR, Grosch EJ, Chetiyawardana AD, Reed NS, Widmer B, Stenning SP: Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol 1999;17:1146.
7.
Rüther U, Dieckmann K, Bussar-Maatz R, Eisenberger F: Second malignancies following pure seminoma. Oncology 2000;58:75–82.
8.
Lederman GS, Sheldon TA, Chaffey JT, Herman TS, Gelman RS, Coleman CN: Cardiac disease after mediastinal irradiation for seminoma. Cancer 1987;60:772–776.
9.
Hanks GE, Peters T, Owen J: Seminoma of the testis: long-term beneficial and deleterious results of radiation. Int J Radiat Oncol Biol Phys 1992;24:913–919.
10.
Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, Van Leeuwen FE, Kohler BA, Pukkala E, Lynch CF, Andersson M, Bergfeldt K, Clarke EA, Wiklund T, Stoter G, Gospodarowicz M, Sturgeon J, Fraumeni JF Jr, Boice JD Jr: Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89:1429–1439.
11.
Weissbach L: Guidelines for the diagnosis and therapy of testicular cancer and new developments. Urol Int 1999;63:46–56.
12.
Tandstad T, Klepp O: Neuron-specific enolase in testicular cancer – clinical experiences with serum neuron-specific enolase in patients with testicular cancer at diagnosis and during follow-up. Acta Oncol 2003;42:202–206.
13.
von der Maase H, Specht L, Jacobsen GK, Jakobsen A, Madsen EL, Pedersen M, Rorth M, Schultz H: Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer 1993;29A:1931–1934.
14.
Horwich A: Surveillance for stage I seminoma of the testis; in Horwich A: Testicular Cancer. Investigation and Management, ed 2. London, Chapman & Hall Medical, 1996, pp 109–116.
15.
Warde P, Gospodarowicz MK, Banerjee D, Panzarella T, Sugar L, Catton CN, Sturgeon JF, Moore M, Jewett MA: Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. J Urol 1997;157:1705–1709; discussion 1709–1710.
16.
Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, von der Maase H: Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002;22:4448–4452.
17.
Dieckmann KP, Loy V: Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. J Clin Oncol 1996;14:3126–3132.
18.
Harland SJ, Cook PA, Fossa SD, Horwich A, Mead GM, Parkinson MC, Roberts JT, Stenning SP: Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. J Urol 1998;160:1353–1357.
19.
Heidenreich A, Weissbach L, Holtl W, Albers P, Kliesch S, Kohrmann KU, Dieckmann KP; German Testicular Cancer Group: Organ sparing surgery for malignant germ cell tumor of the testis. J Urol 2001;166:2161–2165.
20.
Bayley A, Warde P, Milosevic M, Gospodarowicz M: Surveillance for stage I testicular seminoma. A review. Urol Oncol 2001;6:139–143.
21.
Mykletun A, Dahl AA, Haaland CF, Bremnes R, Dahl O, Klepp O, Wist E, Fossa SD: Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. J Clin Oncol 2005;23:3061–3068.
22.
Fossa SD, Moynihan C, Serbouti S: Patients’ and doctors’ perception of long-term morbidity in patients with testicular cancer clinical stage I. A descriptive pilot study. Support Care Cancer 1996;4:118–128.
23.
Hao D, Seidel J, Brant R, Alexander F, Ernst DS, Summers N, Russell JA, Stewart DA: Compliance of clinical stage I nonseminomatous germ cell tumor patients with surveillance. J Urol 1998;160:768–771.
24.
Aparicio J,Germa JR, Garcia Del Muro X, et al: Risk-adapted management of stage I seminoma: the second Spanish Germ Cell Cancer Group (GG) study. Proc Am Soc Clin Oncol 2004;22:4518.
25.
Jones WG, Fossa SD, Mead GM, Roberts JT, Sokal M, Horwich A, Stenning SP: Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 2005;23:1200–1208.
26.
Logue JP, Harris MA, Livsey JE, Swindell R, Mobarek N, Read G: Short course para-aortic radiation for stage I seminoma of the testis. Int J Radiat Oncol Biol Phys 2003;57:1304–1309.
27.
Santoni R, Barbera F, Bertoni F, De Stefani A, Livi L, Paiar F, Scoccianti S, Magrini SM: Stage I seminoma of the testis: a bi-institutional retrospective analysis of patients treated with radiation therapy only. BJU Int 2003;92:47–52.
28.
Joos H, Sedlmayer F, Gomahr A, Rahim HB, Frick J, Kogelnik HD, Rettenbacher L: Endocrine profiles after radiotherapy in stage I seminoma: impact of two different radiation treatment modalities. Radiother Oncol 1997;43:159–162.
29.
Oliver TM, von der Maase, H on behalf of the MRC Testis Tumour Group and the EORTC GU Group: A randomised comparison of single agent carboplatin with radiotherapy in the adjuvant treatment of stage I seminoma of the testis following orchidectomy: MRC TE19/EORTC 30982 (abstract 4517). Proc Am Soc Clin Oncol 2004;23:385.
30.
Krege S, Kalund G, Otto T, Goepel M, Rubben H: Phase II study: adjuvant single-agent carboplatin therapy for clinical stage I seminoma. Eur Urol 1997;31:405–407.
31.
Steiner H, Holtl L, Wirtenberger W, Berger AP, Bartsch G, Hobisch A: Long-term experience with carboplatin monotherapy for clinical stage I seminoma: a retrospective single-center study. Urology 2002;60:324–328.
32.
Dieckmann KP, Bruggeboes B, Pichlmeier U, Kuster J, Mullerleile U, Bartels H: Adjuvant treatment of clinical stage I seminoma: is a single course of carboplatin sufficient? Urology 2000;55:102–106.
33.
Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, Dearnaley DP: Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003;21:1513–1523.
34.
Zagars GK, Ballo MT, Lee AK, Strom SS: Mortality after cure of testicular seminoma. J Clin Oncol 2004;22:640–647.
35.
Glanzmann C, Kaufmann P, Jenni R, Hess OM, Huguenin P: Cardiac risk after mediastinal irradiation for Hodgkin’s disease. Radiother Oncol 1998;46:51–62.
36.
Huyghe E, Matsuda T, Daudin M, Chevreau C, Bachaud JM, Plante P, Bujan L, Thonneau P: Fertility after testicular cancer treatments: results of a large multicenter study. Cancer 2004;100:732–737.
37.
Nalesnik JG, Sabanegh ES Jr, Eng TY, Buchholz TA: Fertility in men after treatment for stage 1 and 2A seminoma. Am J Clin Oncol 2004;27:584–588.
38.
Dieckmann KP, Wegner HE, Krain J: Multiple primary neoplasms in patients with testicular germ cell tumor. Oncology 1994;51:450–458.
39.
Rubin P, Zagars G, Chuang C, Thomas EM: Hodgkin’s disease: is there a price for successful treatment? A 25-year experience. Int J Radiat Oncol Biol Phys 1986;12:153–166.
40.
Fossa SD, Langmark F, Aass N, Andersen A, Lothe R, Borresen AL: Second non-germ cell malignancies after radiotherapy of testicular cancer with or without chemotherapy. Br J Cancer 1990;61:639–643.
41.
Mueller T, Hobisch A, Rein P, Aufderklamm J, Akkad T, Gozzi C, Bartsch G, Steiner H: Long term experience with carboplatin monotherapy for clinical stage I seminomas (abstract 425). Annual Meeting of the American Urological Association, San Antonio, 2005.
42.
Escudero MC, Lassaletta A, Sevilla J, Fernandez-Plaza S, Perez A, Diaz MA, Madero L: Chemotherapy-related secondary acute myeloid leukemia in patients diagnosed with osteosarcoma. J Pediatr Hematol Oncol 2004;26:454–456.
43.
Nishimura S, Sato T, Ueda H, Ueda K: Acute myeloblastic leukemia as a second malignancy in a patient with hereditary retinoblastoma. J Clin Oncol 2001;19:4182–4183.
44.
Tasaka T, Matsuhashi Y, Uehara E, Tamura T, Kakazu N, Abe T, Nagai M: Secondary acute monocytic leukemia with a translocation t(8;16)(p11;p13): case report and review of the literature. Leuk Lymphoma 2004;45:621–625.
45.
Travis LB, Holowaty EJ, Bergfeldt K, Lynch CF, Kohler BA, Wiklund T, Curtis RE, Hall P, Andersson M, Pukkala E, Sturgeon J, Stovall M: Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999;340:351–357.
46.
Sharda NN, Kinsella TJ, Ritter MA: Adjuvant radiation versus observation: a cost analysis of alternate management schemes in early-stage testicular seminoma. J Clin Oncol 1996;14:2933–2939.
47.
Warde P, Gospodarowicz MK, Panzarella T, Chow E, Murphy T, Catton CN, Sturgeon JF, Moore M, Milosevic M, Jewett MA: Long term outcome and cost in the management of stage I testicular seminoma. Can J Urol 2000;7:967–972; discussion 973.
© 2005 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.